Svetlana Lucas
Director/Board Member bij ATYR PHARMA, INC.
Vermogen: 11 700 $ op 31-03-2024
Profiel
Dr. Svetlana Lucas is an Independent Director at aTyr Pharma, Inc. and a Chief Business Officer at Scribe Therapeutics, Inc. She is on the Board of Directors at aTyr Pharma, Inc. Dr. Lucas was previously employed as a Senior Vice President-Business Development by Tizona Therapeutics, Inc. and a Head-Oncology & Inflammation by Amgen, Inc. She received her undergraduate degree from Moscow State University Lomonosov and a doctorate degree from California Institute of Technology.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ATYR PHARMA, INC.
0.01% | 01-03-2024 | 6 000 ( 0.01% ) | 11 700 $ | 31-03-2024 |
Actieve functies van Svetlana Lucas
| Bedrijven | Functie | Begin |
|---|---|---|
| ATYR PHARMA, INC. | Director/Board Member | 28-06-2019 |
Scribe Therapeutics, Inc.
 Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Corporate Officer/Principal | - |
Eerdere bekende functies van Svetlana Lucas
| Bedrijven | Functie | Einde |
|---|---|---|
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01-06-2019 |
| AMGEN INC. | Corporate Officer/Principal | 01-07-2015 |
Opleiding van Svetlana Lucas
| California Institute of Technology | Doctorate Degree |
| Moscow State University Lomonosov | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ATYR PHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Health Technology |
